Human breast cancer: correlation study between HER-2/neu amplification and prognostic factors in an unselected population.
In 199 breast cancers, HER-2/neu amplification was analyzed by Southern blotting (149 cases) and by slot blotting (149 cases), with 99 cases studied using both techniques. There were 18.8% amplified tumors (> or = 2 copies) by Southern blotting and 15.4% by slot blotting. The difference in the percentages of amplified tumors was not statistically significant (p = 0.44). There was a correlation between HER-2/neu amplification and the SBR grade (p = 0.046): this correlation relied on the absence of amplification in the GI tumors. In a subset study, the negativity of the progesterone receptor content was correlated with HER-2/neu amplification in the node positive (p = 0.02), the pre-menopausal (p = 0.04) and the pre-menopausal node positive (p = 0.002) patients. In the literature as in our results, amplification appears to be correlated with poor prognostic factors. However, in a subgroup with most of the favorable prognostic factors: positive estrogen and progesterone receptor contents and node negativity, the frequency of amplified tumors (19.4%, n = 67) was the same as that observed in the whole group (16.6%, n = 199). This result may suggest that the HER-2/neu amplification could act as an independent prognostic factor.
Descotes
F
F
Service de Biochimie Biologie Moléculaire, CHU Besançon, France.
Pavy
J J
JJ
Adessi
G L
GL
D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D015139:Blotting, Southern; D001943:Breast Neoplasms / Q000235:genetics* / Q000401:mortality; D005260:Female; D005784:Gene Amplification / Q000235:genetics*; D006801:Humans; D008875:Middle Aged; D009856:Oncogene Proteins, Viral / Q000235:genetics*; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases
D009856:Oncogene Proteins, Viral; D018719:Erb-b2 Receptor Tyrosine Kinases